BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech ...

Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ...

Bristol Myers Squibb (NYSE: BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ: BNTX) immunotherapy bispecific antibody BNT327 for solid tumors.

Bristol-Myers Squibb and BioNTech have entered a collaboration to co-develop and commercialize BioNTech's BNT327, a clinical-stage PD-L1/VEGF-A bispecific antibody for treating cancer.

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report that doubled year-over-year revenue to €260.8 million, well above analysts’ ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

The deal grants Bristol-Myers rights to BNT327, a cancer immunotherapy compound that BioNTech originally licensed from China’s biotech company Biotheus in 2023, which it later acquired for ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific ...

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types ...